Claims
- 1. A method for promoting neurite outgrowth or neurite cell adhesion comprising, introducing an isolated nucleic acid molecule which encodes an .alpha. 2,8 polysialyl transferase enzyme operably linked to a promoter into an isolated nerve cell and culturing said nerve cell to express sufficient .alpha. 2,8 polysialyl transferase to promote neurite outgrowth or neurite cell adhesion.
- 2. A method for promoting neurite outgrowth or neurite cell adhesion comprising, introducing an isolated nucleic acid molecule which encodes an .alpha. 2,8 polysialyl transferase enzyme operably linked to a promoter into a substrate cell and co-culturing said substrate cell with a nerve cell, wherein said substrate cell expresses sufficient .alpha. 2,8 polysialyl transferase to promote neurite outgrowth or neurite cell adhesion.
- 3. The method of claim 1 or 2, wherein said enzyme is a rodent enzyme.
- 4. The method of claim 1 or 2, wherein said enzyme is a human enzyme.
- 5. The method of claim 1 or 2, wherein said isolated nucleic acid molecule has a nucleotide sequence consisting of SEQ ID NO: 1.
- 6. The method of claim 1 or 2, wherein said isolated nucleic acid molecule has a nucleotide sequence consisting of SEQ ID NO: 7.
- 7. The method of claim 1 or 2, wherein said isolated nucleic acid molecule encodes a protein having the amino acid sequence set forth in SEQ ID NO: 2.
- 8. The method of claim 1 or 2, wherein said isolated nucleic acid molecule encodes a protein having the amino acid sequence set forth in SEQ ID NO: 8.
- 9. The method of claim 1 or 2, wherein said isolated nucleic acid molecule consists of nucleotides 301-1377 of SEQ ID NO: 1.
- 10. The method of claim 1 or 2, wherein said isolated nucleic acid molecule consists of nucleotides 213-1289 of SEQ ID NO: 7.
- 11. The method of claim 1 or 2, wherein said isolated nucleic acid molecule has a complement which hybridizes to nucleotides 301-1377 of SEQ ID NO: 1.
- 12. The method of claim 1 or 2, wherein said isolated nucleic acid molecule has a complement which hybridizes to nucleotides 213-1289 of SEQ ID NO: 7.
- 13. The method of claim 1 or 2, wherein said .alpha.-2,8 polysialyl transferase is soluble.
- 14. The method of claim 13, wherein said soluble .alpha.-2,8 polysialyl transferase has an amino acid sequence which consists of amino acids 21-359 of SEQ ID NO: 2, amino acids 26-359 of SEQ ID NO: 2, amino acids 31-359 of SEQ ID NO: 2, amino acids 21-359 of SEQ ID NO: 8, amino acids 26-359 of SEQ ID NO: 8, amino acids 31-359 of SEQ ID NO: 8, or amino acids 40-359 of SEQ ID NO: 8.
- 15. The method of claim 1 or 2, comprising introducing said isolated nucleic acid molecule in the form of an expression vector.
- 16. The method of claim 15, wherein said expression vector comprises the nucleotide sequence set forth in SEQ ID NO: 1.
- 17. The method of claim 15, wherein said expression vector comprises the nucleotide sequence set forth in SEQ ID NO: 7.
- 18. The method of claim 15, wherein said expression vector comprises nucleotides 301-1377 of SEQ ID NO: 1, or nucleotides 213-1289 of SEQ ID NO: 7.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/EP94/04289 |
Dec 1994 |
WOX |
|
Parent Case Info
This application is a Divisional of Ser. No. 08/503,133 filed Jul. 17, 1995, now U.S. Pat. No. 5,747,326 filed May 5, 1998 which is a continuation-in-part of PCT Application PCT/EP94/04289 filed on Dec. 22, 1994 designating the United States. Thus, priority is claimed pursuant to 35 U.S.C. .sctn.365(a), (b) and (c). Portions of the subject matter described herein were developed with funds from NIH grant CA 33895. The U.S. government may have rights to these features of the invention.
Government Interests
Funds from NIH Grant CA 33895 were used in the development of portions of the invention described herein. Thus the U.S. government may have rights to portions of this invention.
Non-Patent Literature Citations (4)
Entry |
Friedmann, T. Gene therapy for Neurological Disorders. TIG, vol. 10, No. 6, pp. 210-214, Jun. 1994. |
Yamamoto et al. Alpha 2,6-Sialyltransferase Gene Transfectin into a Human Glioma Cell Line (U373 MG) Resuslts in Decreased Invasivity. J. of Neurochem., vol. 68, No. 6, pp. 2566-2576, 1997. |
Eckhardt et al. Molecular Characterization of Eukaryotic Polysialytrasnferase-1. Nature, vol. 373, pp. 715-718, Feb. 23, 1995. |
Orkin et al. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy. Distributed by the National Institutes of Health, Bethesda, MD. www.nih.gov. Dec. 7, 1995. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
503133 |
|
|